Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Episodic antiretroviral treatment harms patients

Enrolment of subjects in a large international HIV/AIDS trial to compare episodic with continuous antiretroviral treatment has ceased. The decision follows an analysis of interim study data, which showed that subjects on episodic treatment had more than twice the risk of disease progression compared with those taking continuous antiretroviral therapy.

The US trial, known as SMART (strategies for management of antiretroviral therapy), was designed to investigate whether patients could be spared some of the toxic effects of long-term antiretroviral therapy by using a CD4 cell-guided episodic “drug conservation” strategy. However, in addition to the increased risk of clinical AIDS or death, investigators also saw an increase in major antiretroviral toxicities such as cardiovascular, kidney and liver complications.

Citation: The Pharmaceutical Journal URI: 10020829

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.